MedTrace Logo

Korean Lung Cancer Screening Project

NCT03394703 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8000

Last updated 2018-01-09

No results posted yet for this study

Summary

Lung cancer is by far the leading cause of cancer death and has a lower relative survival rate than other types of cancer because most lung cancers are detected at an advanced stage when they are first diagnosed.

Recently, a randomized control trial suggests that low-dose computed tomography (LDCT) enables an early stage detection and it has been increasingly accepted as an efficient screening method for high-risk individuals to reduce lung cancer mortality.

In 2011, The National Lung Screening Trial (NLST) in the U.S. has produced results that screening high-risk smoking groups (who have at least 30 pack-year smoking history and currently smoke or have quit within the past 15 years) aged 55 to 74 years with LDCT reduced lung cancer mortality by 20%.

Based on the evidence, Korean National Cancer Center has developed and published the guideline of lung cancer screening using LDCT for high-risk populations in 2015. The guideline recommends annual LDCT screening for high-risk smoking groups aged 55 to 74 years, with at least 30 pack-year smoking history and current smokers or past smokers who quit smoking within 15 years.

The Korean Lung Cancer Screening project (K-LUCAS), a nationwide, multicenter, prospective study started to evaluate the effectiveness and feasibility of lung cancer screening with LDCT for considering implementation of a national lung cancer screening program in Korea.

Conditions

Sponsors & Collaborators

  • Korean Association for Lung Cancer

    collaborator UNKNOWN

  • The Korean Society of Radiology

    collaborator UNKNOWN

  • The Korea Academy of Tuberculosis and Respiratory diseases

    collaborator UNKNOWN

  • The Korean Academy of Family Medicine

    collaborator UNKNOWN

  • The Korean Society for Preventive Medicine

    collaborator UNKNOWN

  • National Cancer Center, Korea

    lead OTHER_GOV

Eligibility

Min Age
55 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03394703 on ClinicalTrials.gov